Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CSNK1E_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CSNK1E_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CSNK1E_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CSNK1E_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CSNK1E_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CSNK1E_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CSNK1E_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CSNK1E_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CSNK1E_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
GO:00902639 | Oral cavity | OSCC | positive regulation of canonical Wnt signaling pathway | 62/7305 | 106/18723 | 3.72e-05 | 3.31e-04 | 62 |
GO:000762316 | Oral cavity | OSCC | circadian rhythm | 110/7305 | 210/18723 | 5.40e-05 | 4.48e-04 | 110 |
GO:005110019 | Oral cavity | OSCC | negative regulation of binding | 87/7305 | 162/18723 | 1.00e-04 | 7.54e-04 | 87 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
GO:00329229 | Oral cavity | OSCC | circadian regulation of gene expression | 40/7305 | 68/18723 | 7.28e-04 | 3.98e-03 | 40 |
GO:00301779 | Oral cavity | OSCC | positive regulation of Wnt signaling pathway | 73/7305 | 140/18723 | 1.06e-03 | 5.46e-03 | 73 |
GO:003090116 | Oral cavity | OSCC | midbrain development | 46/7305 | 90/18723 | 1.30e-02 | 4.33e-02 | 46 |
GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
GO:0043161110 | Oral cavity | LP | proteasome-mediated ubiquitin-dependent protein catabolic process | 190/4623 | 412/18723 | 1.08e-21 | 2.93e-19 | 190 |
GO:0042176110 | Oral cavity | LP | regulation of protein catabolic process | 177/4623 | 391/18723 | 3.00e-19 | 5.87e-17 | 177 |
GO:0045862110 | Oral cavity | LP | positive regulation of proteolysis | 165/4623 | 372/18723 | 5.40e-17 | 8.46e-15 | 165 |
GO:1903362110 | Oral cavity | LP | regulation of cellular protein catabolic process | 119/4623 | 255/18723 | 1.52e-14 | 1.76e-12 | 119 |
GO:1903050110 | Oral cavity | LP | regulation of proteolysis involved in cellular protein catabolic process | 101/4623 | 221/18723 | 7.00e-12 | 5.48e-10 | 101 |
GO:0061136110 | Oral cavity | LP | regulation of proteasomal protein catabolic process | 89/4623 | 187/18723 | 8.05e-12 | 6.15e-10 | 89 |
GO:0009896110 | Oral cavity | LP | positive regulation of catabolic process | 187/4623 | 492/18723 | 2.30e-11 | 1.58e-09 | 187 |
GO:0045732110 | Oral cavity | LP | positive regulation of protein catabolic process | 103/4623 | 231/18723 | 2.68e-11 | 1.81e-09 | 103 |
GO:0032434110 | Oral cavity | LP | regulation of proteasomal ubiquitin-dependent protein catabolic process | 67/4623 | 134/18723 | 2.09e-10 | 1.13e-08 | 67 |
GO:0031331110 | Oral cavity | LP | positive regulation of cellular catabolic process | 163/4623 | 427/18723 | 3.03e-10 | 1.59e-08 | 163 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK1E | SNV | Missense_Mutation | novel | c.29G>T | p.Arg10Leu | p.R10L | P49674 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.82) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CSNK1E | SNV | Missense_Mutation | | c.874N>T | p.Met292Leu | p.M292L | P49674 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1E | SNV | Missense_Mutation | rs771808437 | c.821N>A | p.Arg274His | p.R274H | P49674 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.972) | TCGA-B6-A0RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CSNK1E | SNV | Missense_Mutation | | c.795C>G | p.Asp265Glu | p.D265E | P49674 | protein_coding | deleterious_low_confidence(0.01) | benign(0.043) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
CSNK1E | SNV | Missense_Mutation | | c.385N>A | p.Val129Ile | p.V129I | P49674 | protein_coding | tolerated_low_confidence(1) | benign(0.007) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1E | SNV | Missense_Mutation | rs749796700 | c.1103N>T | p.Ser368Leu | p.S368L | P49674 | protein_coding | deleterious_low_confidence(0.04) | benign(0.079) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1E | SNV | Missense_Mutation | | c.799T>G | p.Ser267Ala | p.S267A | P49674 | protein_coding | tolerated_low_confidence(0.27) | benign(0.014) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CSNK1E | SNV | Missense_Mutation | | c.379N>T | p.Arg127Trp | p.R127W | P49674 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CSNK1E | SNV | Missense_Mutation | novel | c.158N>T | p.Ser53Ile | p.S53I | P49674 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.987) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CSNK1E | SNV | Missense_Mutation | | c.256N>T | p.Gly86Trp | p.G86W | P49674 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | inhibitor | 310264697 | UMBRALISIB | |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | inhibitor | HTS-466284 | CHEMBL261454 | 19035792 |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | inhibitor | 328083473 | CHEMBL1951415 | |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | | heroin | DIACETYLMORPHINE | |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | inhibitor | 249565730 | CHEMBL2069623 | |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | | SB-202190 | SB-202190 | 22951114 |
1454 | CSNK1E | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, DNA REPAIR | inhibitor | 178102608 | IC261 | |